Hrt Financial LP Immunovant, Inc. Transaction History

Hrt Financial LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$31.31 - $44.19 $2.9 Million - $4.1 Million	92,731 New	92,731 $3.91 Million
Q3 2022 Nov 14, 2022	BUY	$3.93 - $6.37 $564,701 - $915,305	143,690 New	143,690 $801,000
Q2 2022 Aug 12, 2022	SELL	$3.38 - $5.65 $314,154 - $525,139	-92,945 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$5.06 - $8.77 $10,453 - $18,118	2,066 Added 2.27%	92,945 $512,000
Q4 2021 Feb 14, 2022	SELL	$7.33 - $9.32 $1.12 Million - $1.43 Million	-153,002 Reduced 62.74%	90,879 $774,000
Q3 2021 Nov 15, 2021	BUY	$7.01 - $11.37 $455,909 - $739,470	65,037 Added 36.37%	243,881 $2.12 Million
Q2 2021 Aug 16, 2021	BUY	$9.4 - $16.85 $1.68 Million - $3.01 Million	178,844 New	178,844 $1.89 Million

212

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

Stay updated on Hrt Financial LP with notifications on news.